NewsRx

Search our medical news database

Toxicity

Thiacetazone's Not As Toxic in HIV+ As Believed

Published in TB and Outbreaks Week, October 2nd, 1995

A study from Tanzania suggests that the serious cutaneous side effects reported in HIV positive tuberculosis patients treated with thiacetazone may be rarer than previously reported.

The study found that improved management of the widely used anti-tuberculosis agent in this group of patients may allow its continued use, even in countries with widespread HIV infection.

Thiacetazone, one of the semicarbazones, has become an important weapon in tuberculosis control throughout developing countries because it is inexpensive, efficacious and widely available.

During the past few years, however, serious cutaneous reactions to...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week


More Articles from TB and Outbreaks Week

NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook